|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | CONSORT 2010说明与详述:报告平行对照随机临床试验指南的更新显示文摘大量证据显示随机对照临床试验(randomised controlled trial,RCT)的报告质量不理想。报告不透明,则读者既不能评判试验结果是否真实可靠,也不能从中提取可用于系统综述的信息。最近的方法学分析表明,报告不充分和设计不合理与对治疗效果产生评价偏倚有关。这种系统误差对RCT损害严重,而RCT正是以其能减少或避免偏倚而被视为评价干预措施的金标准。为了提高RCT的报告质量,一个由专家和编辑组成的工作组制定了临床试验报告的统一标准(Consolidated Standards of Reporting Trials,CONSORT)声明。CONSORT声明于1996年首次发表,并于2001年更新。声明由对照检查清单和流程图组成,供作者在报告RCT时使用。许多核心医学期刊和主要国际性编辑组织都已认可CONSORT声明。该声明促进了对RCT的严格评价和解释。2001年,在对CONSORT进行修订时,人们就已经清楚地认识到,解释和说明制定CONSORT声明的原理,有助于研究人员等撰写或评价临床试验报告。一篇CONSORT说明与详述文章于2001年同2001版CONSORT声明一起发表。2007年1月的专家会议之后,对CONSORT声明作了进一步修订并已发表,即'CONSORT2010声明'。这次更新对原版对照检查清单作了文字上的修改,使其更为明晰,并收入了与一些新近才认识到的主题相关的建议,如选择性报告结局产生的偏倚。说明与详述文件旨在加强人们对CONSORT声明的理解、应用和传播,这次也作了大量修订,对每一项新增或更新的清单条目的含义和增改理由进行了解释,提供了优秀的报告实例,还尽可能地提供了相关的经验性研究的参考文献。文中收入了若干流程图实例。'CONSORT2010声明'、其说明与详述文件,以及相关网站(www.consort-statement.org),对于改进随机临床试验报告必将有所裨益。 | David Moher Sally Hopewell Kenneth F Schulz Victor Montori Peter C Gφtzsche P J Devereaux Diana Elbourne Matthias Egger Douglas G Altman 周庆辉 卞兆祥 刘建平 | 2010 | 中西医结合学报2010，8，8： | 318 |
| 2 | CONSORT 2010声明:报告平行对照随机临床试验指南的更新显示文摘CONSORT声明被广泛用于提高随机对照临床试验的报告质量。Kenneth Schulz等对CONSORT声明的最新版本CONSORT2010作了详细说明,该版本基于新获得的方法学证据和经验的积累对报告指南作了更新。为了鼓励更多的人使用'CONSORT2010声明',本文可从bmj.com免费获取,也将在Lancet,Obstetrics and Gynecology,PLoS Medicine,Annals of Internal Medicine,Open Medicine,Journal of Clinical Epidemiology,BMC Medicine和Trials等杂志发表。 | Kenneth F Schulz Douglas G Altman David Moher 周庆辉 卞兆祥 刘建平 | 2010 | 中西医结合学报2010，8，7： | 45 |
| 3 | 针刺临床试验干预措施报告标准的修订:CONSORT声明的扩展显示文摘'针刺临床试验干预措施报告标准'(STandards for Reporting Interventions in Clinical Trials of Acupuncture,STRICTA)于2001年和2002年在5种期刊上发表。该指南以对照检查清单及解释的形式供作者和期刊编辑使用,旨在提高针刺临床试验报告的质量,尤其是对其中干预措施的报告,因而有助于对这些试验的解释和重复。随后对STRICTA的应用及影响的述评都强调了STRICTA的价值,也提出了改进和修订的建议。为使修订过程顺利进行,STRICTA工作组、CONSORT工作组和中国Cochrane中心于2008年开始合作。召集成立的有47名成员的专家组对清单的修改稿提出了电子版反馈意见。在后来于弗莱堡(Freiburg)召开的见面会上,由21名专家组成的工作组进一步修订了STRICTA对照检查清单,并计划如何对其进行发布。新的STRICTA对照检查清单作为CONSORT的正式扩展版,包含6项条目及17条二级条目。这些条目为报告针刺治疗的合理性、针刺的细节、治疗方案、其他干预措施、治疗师的背景以及对照或对照干预提供了指南。而且,作为修订工作的一部分,对每一条目作了详尽解释,并针对每一条目给出了报告良好的实例。此外,STRICTA中的'对照'(controlled)一词被替换成了'临床'(clinical),以示STRICTA适用于更广泛的各类临床评价设计,包括非对照结局研究和病例报道。修订的STRICTA对照检查清单有望与CONSORT声明及其非药物治疗扩展版一起共同提高针刺临床试验的报告质量。 | Hugh MacPherson Douglas G Altman Richard Hammerschlag 李幼平 吴泰相 Adrian White David Moher 刘建平 | 2010 | 中西医结合学报2010，8，9： | 33 |
| 4 | The paternal epigenome and embryogenesis: poising mechanisms for development显示文摘父亲的贡献的范围长在早胚胎的开发期间被认为有限。在在整个精子发生的染色质结构的戏剧的变化被认为在 DNA 蓝图上 epigenetic 规定的复杂的层让精子空,因此把那条规定的平衡留给卵母细胞。然而, epigenetics 和男因素不孕的地里的最近的工作放了这长抓住、现在争论的教义,在一盏新灯。在发展中的精子房间调查染色质和 epigenetic 修正的漂亮研究提供了可以在发展中的胚胎为父亲的 epigenome 建立一个更关键的角色的新卓见。进染色质的 DNA methylation, histone 尾巴修正,指向的 histone 保留和鱼精朊加入在发展中的精子房间有大影响。在任何这些 epigenetic 标记的建立或维护的不安被表明了影响富饶地位,在严厉从变化对温和灾难。精子要求染色质的这个无数的结构的变化不仅在整个精子发生和未来交货起一个保护的作用到 DNA 到卵,而且,它出现,贡献未来胚胎的发展节目。这评论将集中于我们精子的 epigenetics 的当前的理解。我们将讨论导致对开发必要的基因在胚胎的开发,其混乱可以导致减少的肥沃早为激活被平衡的精子特定的染色质修正。 | Timothy G Jenkins Douglas T Carrell | 2011 | Asian Journal of Andrology2011，13，1： | 14 |
| 5 | Enteral stents for the management of malignant colorectal obstruction显示文摘Colorectal cancer(CRC) is the 3rd most common cancer in the United States with more than 10000 new cases diagnosed annually. Approximately 20% of patients with CRC will have distant metastasis at time of diagnosis, making them poor candidates for primary surgical resection. Similarly, 8%-25% of patients with CRC will present with bowel obstruction and will require palliative therapy. Emergent surgical decompression has a high mortality and morbidity, and often leads to a colostomy which impairs the patient's quality of life. In the last decade, there has been an increasing use of colonic stents for palliative therapy to relieve malignant colonic obstruction. Colonic stents have been shown to be effective and safe to treat obstruction from CRC, and are now the therapy of choice in this scenario. In the setting of an acute bowel obstruction in patients with potentially resectable colon cancer, stents may beused to delay surgery and thus allow for decompression, adequate bowel preparation, and optimization of the patient's condition for curative surgical intervention. An overall complication rate(major and minor) of up to 25% has been associated with the procedure. Long term failure of stents may result from stent migration and tumor ingrowth. In the majority of cases, repeat stenting or surgical intervention can successfully overcome these adverse effects. | Jeremy Kaplan Anna Strongin Douglas G Adler Ali A Siddiqui | 2014 | World Journal of Gastroenterology2014，20，37： | 13 |
| 6 | Increased hepcidin expression in colorectal carcinogenesis显示文摘AIM:To investigate whether the iron stores regulator hepcidin is implicated in colon cancer-associated anae- mia and whether it might have a role in colorectal car- cinogenesis. METHODS: Mass spectrometry (MALDI-TOF MS and SELDI-TOF MS) was employed to measure hepcidin in urine collected from 56 patients with colorectal cancer. Quantitative Real Time RT-PCR was utilised to determine hepcidin mRNA expression in colorectal cancer tissue. Hepcidin cellular localisation was determined using im- munohistochemistry. RESULTS: We demonstrate that whilst urinary hepcidin expression was not correlated with anaemia it was posi- tively associated with increasing T-stage of colorectal cancer (P < 0.05). Furthermore, we report that hepcidin mRNA is expressed in 34% of colorectal cancer tissue specimens and was correlated with ferroportin repres- sion. This was supported by hepcidin immunoreactivity in colorectal cancer tissue. CONCLUSION: We demonstrate that systemic hepcidin expression is unlikely to be the cause of the systemic anaemia associated with colorectal cancer. However, we demonstrate for the first time that hepcidin is expressed by colorectal cancer tissue and that this may represent a novel oncogenic signalling mechanism. | Douglas G Ward Keith Roberts Matthew J Brookes Howard Joy Ashley Martin Tariq Ismail Robert Spychal Tariq Iqbal Chris Tselepis | 2008 | World Journal of Gastroenterology2008，14，9： | 12 |
| 7 | 加强流行病学中观察性研究报告质量(STROBE)声明:观察性研究报告规范显示文摘很多生物医学研究都是观察性的。但对这类研究的报告却通常不完整,从而限制了对其优缺点及普适性的评价。“加强流行病学中观察性研究报告质量(STROBE)”工作组针对一篇完整明确的观察性研究报告应包括的内容提供了一套建议。建议涵盖了流行病学研究的三种主要设计类型:队列设计、病例对照设计和横断面设计。2004年9月,我们召开了为期2天的研讨会,与会的方法学专家、研究人员和期刊编辑共同起草了一份观察性研究报告应纳入的条目清单草案。此后,又通过协调小组数次会议及与有关人员电子邮件讨论等对该草案进行了修改,纳入了经验性证据和方法学方面的意见。通过研讨会及之后反复的咨询和修订,我们制定出了一个包含22个条目的清单(STROBE声明),分为论文的题目、摘要、引言、方法、结果和讨论等部分。其中18个条目适用于所有三种主要的观察性研究设计,其余4个条目则专门用于队列、病例一对照或横断面设计。详细的解释和示范文件已另行发表,在《公共科学图书馆一医学》(PLoS Medicine)、《内科学年报》(Annalsof Internal Medicine)和《流行病学》(Epidemiology)的网站可以免费获得。我们希望STROBE声明能有助于改善观察性研究报告的质量。 | Erikvon Elm Douglas G Altman Matthias Egger Stuart J Pocock Peter C G tzsche Jan P Vandenbroucke 赵乐(译) 邹光勇(审) 杜怀东(审) | 2008 | 世界临床医学2008，2，1： | 12 |
| 8 | 报告随机对照试验的CONSORT声明修订版:说明与详述(二)显示文摘 | Douglas G. Altman Kenneth F. Schulz David Moher Matthias Egger Frank Davidoff Diana Elbourne Peter C. Gtzsch Thomas Lang 刘雪梅 | 2005 | 中国循证医学杂志2005，5，10： | 8 |
| 9 | Osteoclastic and pleomorphic giant cell tumors of the pancreas:A review of clinical,endoscopic,and pathologic features显示文摘Giant cell tumors of the pancreas come in three varieties-osteoclastic,pleomorphic,and mixed histology.These tumors have distinctive endoscopic,clinical,and cytological features.Giant cell tumors have a controversial histogenesis,with some authors favoring an epithelial origin and others favoring a mesenchymal origin.The true origin of these lesions remains unclear at this time.These are also very rare tumors but proper identification and differentiation from more common pancreatic adenocarcinoma is important.The risk factors of these tumors and the prognosis may be different from those associated with standard pancreatic adenocarcinoma.Recognition of these differences can significantly affect patient care.These lesions have a unique appearance when imaged with endoscopic ultrasound(EUS),and these lesions can be diagnosed via EUS guided Fine Needle Aspiration(FNA).This manuscript will review the endoscopic,clinical,and pathologic features of these tumors. | Jill C Moore Joel S Bentz Kristen Hilden Douglas G Adler | 2010 | World Journal of Gastrointestinal Endoscopy2010，2，1： | 7 |
| 10 | 报告随机对照试验的CONSORT声明修订版:说明与详述(四)显示文摘Douglas G. Altman1, Kenneth F. Schulz2, David Moher3, Matthias Egger4, Frank Davidoff5, Diana Elbourne6, Peter C. Gtzsch7, Thomas Lang8 for the CONSORT | Douglas G. Altman Kenneth F. Schulz David Moher Matthias Egger Frank Davidoff Diana Elbourne Peter C. Gtzsch Thomas Lang 刘雪梅 | 2005 | 中国循证医学杂志2005，5，12： | 7 |
| 11 | CONSORT说明文件的制定显示文摘 | Douglas G Altman 杜亮 | 2005 | 中国循证医学杂志2005，5，9： | 6 |
| 12 | Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial显示文摘 | Ian M Gralnek Peter D Siersema Zamir Halpern Ori Segol Alaa Melhem Alain Suissa Erwin Santo Alan Sloyer Jay Fenster Leon M G Moons Vincent K Dik Ralph B D’Agostino Douglas K Rex | 2014 | Lancet Oncology2014，，3： | 6 |
| 13 | Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit显示文摘 | Juliana Barr Gilles L. Fraser Kathleen Puntillo E. Wesley Ely Céline Gélinas Joseph F. Dasta Judy E. Davidson John W. Devlin John P. Kress Aaron M. Joffe Douglas B. Coursin Daniel L. Herr Avery Tung Bryce R. H. Robinson Dorrie K. Fontaine Michael A. Ramsa | 2013 | Critical Care Medicine2013，，1： | 6 |
| 14 | 报告随机对照试验的CONSORT声明修订版:说明与详述(一)显示文摘 | Douglas G. Altman Kenneth F. Schulz David Moher Matthias Egger Frank Davidoff Diana Elbourne Peter C. Gφtzsch Thomas Lang 刘雪梅 秦莉 林东涛 邓长安 李静 吴泰相 李幼平 | 2006 | 中国实用内科杂志:临床前沿版2006，26，2： | 6 |
| 15 | Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial显示文摘 | Stephen B Hanauer Brian G Feagan Gary R Lichtenstein Lloyd F Mayer S Schreiber Jean Frederic Colombel Daniel Rachmilewitz Douglas C Wolf Allan Olson Weihang Bao Paul Rutgeerts | 2002 | The Lancet2002，，9317： | 6 |
| 16 | Endoscopic retrograde cholangiopancreatography in cirrhosis-a systematic review and meta-analysis focused on adverse events显示文摘AIM To investigate indications and outcomes of endoscopic retrograde cholangiopancreatography(ERCP) in cirrhotics, especially adverse events. Patients with cirrhosis undergoing ERCP are believed to have increased risk. However, there is a paucity of literature describing the indications and outcomes of ERCP procedures in patients with cirrhosis, especially focusing on adverse events.METHODS We performed a systematic appraisal of major literature databases, including PubMed and EMBASE, with a manual search of literature from their inception until April 2017.RESULTS A total of 6,505 patients from 15 studies were analyzed(male ratio 59%, mean age 59 years), 11% with alcoholic and 89% with non-alcoholic cirrhosis, with 56.2% Child-Pugh class A, and 43.8% class B or C. Indications for ERCP included choledocholithiasis 60.9%, biliary strictures 26.2%, gallstone pancreatitis 21.1% and cholangitis 15.5%. Types of interventions included endoscopic sphincterotomy 52.7%, biliary stenting 16.7% and biliary dilation 4.6%. Individual adverse events included hemorrhage in 4.58%(95%CI: 2.77-6.75%, I^2 = 85.9%), post-ERCP pancreatitis(PEP) in 3.68%(95%CI: 1.83-6.00%, I^2 = 89.5%), cholangitis in 1.93%(95%CI: 0.63-3.71%, I^2 = 87.1%) and perforation in 0.00%(95%CI: 0.00-0.23%, I^2 = 37.8%). Six studies were used for comparison of ERCPrelated complications in cirrhosis vs non-cirrhosis, which showed higher overall rates of complications in cirrhosis patients with pooled OR of 1.63(95%CI: 1.27-2.09, I2 = 65%): higher rates of hemorrhage with OR of 2.05(95%CI: 1.62-2.58, I^2 = 2.1%) and PEP with OR of 1.33(95%CI: 1.04-1.70, I2=65%), but similar cholangitis rates with OR of 1.23(95%CI: 0.67-2.26, I^2 = 44.3%).CONCLUSION There is an overall higher rate of adverse events related to ERCP in patients with cirrhosis, especially hemorrhage and PEP. A thorough risk/benefit assessment should be performed prior to undertaking ERCP in patients with cirrhosis. | Shailender Singh Mashiana Amaninder Singh Dhaliwal Harlan Sayles Banreet Dhindsa Ji Won Yoo Qing Wu shailender singh Ali A Siddiqui Gordon Ohning Mohit Girotra Douglas G Adler | 2018 | World Journal of Gastrointestinal Endoscopy2018，10，11： | 6 |
| 17 | Efficacy of pancreatoscopy for pancreatic duct stones:A systematic review and meta-analysis显示文摘BACKGROUND Pancreatic duct stones can lead to significant abdominal pain for patients.Per oral pancreatoscopy(POP)-guided intracorporal lithotripsy is being increasingly used for the management of main pancreatic duct calculi(PDC)in chronic pancreatitis.POP uses two techniques:Electrohydraulic lithotripsy(EHL)and laser lithotripsy(LL).Data on the safety and efficacy are limited for this procedure.We performed a systematic review and meta-analysis with a primary aim to calculate the pooled technical and clinical success rates of POP.The secondary aim was to assess pooled rates of technical success,clinical success for the two individual techniques,and adverse event rates.AIM To perform a systematic review and meta-analysis of POP,EHL and LL for management of PDC in chronic pancreatitis.METHODS We conducted a comprehensive search of multiple electronic databases and conference proceedings including PubMed,EMBASE,Cochrane,Google Scholar and Web of Science databases(from 1999 to October 2019)to identify studies with patient age greater than 17 and any gender that reported on outcomes of POP,EHL and LL.The primary outcome assessed involved the pooled technical success and clinical success rate of POP.The secondary outcome included the pooled technical success and clinical success rate for EHL and LL.We also assessed the pooled rate of adverse events for POP,EHL and LL including a subgroup analysis for the rate of adverse event subtypes for POP:Hemorrhage,post-endoscopic retrograde cholangiopancreatography pancreatitis(PEP),perforation,abdominal pain,fever and infections.Technical success was defined as the rate of clearing pancreatic duct stones and clinical success as the improvement in pain.Randomeffects model was used for analysis.Heterogeneity between study-specific estimates was calculated using the Cochran Q statistical test and I2 statistics.Publication bias was ascertained,qualitatively by visual inspection of funnel plot and quantitatively by the Egger test.RESULTS A total of 16 studies including 383 patients met the inclusion criteria.The technical success rate of POP was 76.4%(95%CI:65.9-84.5;I2=64%)and clinical success rate was 76.8%(95%CI:65.2-85.4;I2=66%).The technical success rate of EHL was 70.3%(95%CI:57.8-80.3;I2=36%)and clinical success rate of EHL was 66.5%(95%CI:55.2-76.2;I2=19%).The technical success rate of LL was 89.3%(95%CI:70.5-96.7;I2=70%)and clinical success rate of LL was 88.2%(95%CI:66.4-96.6;I2=77%).The incidence of pooled adverse events for POP was 14.9%(95%CI:9.2-23.2;I2=49%),for EHL was 11.2%(95%CI:5.9-20.3;I2=15%)and for LL was 13.1%(95%CI:6.3-25.4;I2=31%).Subgroup analysis of adverse events showed rates of PEP at 7%(95%CI:3.5-13.6;I2=38%),fever at 3.7%(95%CI:2-6.9;I2=0),abdominal pain at 4.7%(95%CI:2.7-7.8;I2=0),perforation at 4.3%(95%CI:2.1-8.4;I2=0),hemorrhage at 3.4%(95%CI:1.7-6.6;I2=0)and no mortality.There was evidence of publication bias based on funnel plot analysis and Egger’s test.CONCLUSION Our study highlights the high technical and clinical success rates for POP,EHL and LL.POP-guided lithotripsy could be a viable option for management of chronic pancreatitis with PDC. | Syed M Saghir Harmeet S Mashiana Babu P Mohan Banreet S Dhindsa Amaninder Dhaliwal Saurabh Chandan Neil Bhogal Ishfaq Bhat Shailender Singh Douglas G Adler | 2020 | World Journal of Gastroenterology2020，26，34： | 5 |
| 18 | CONSORT指南:整群随机试验扩展版显示文摘 | Marion K Campbell Diana R Elbourne Douglas G Altman 杜亮 姚巡 周吉祥 | 2006 | 中国循证医学杂志2006，6，6： | 5 |
| 19 | 连铸板坯和方坯表面缺陷的分析与判定显示文摘无论是钢板、板卷,还是棒材或型材,它们的表面缺陷主要有两种基本来源:轧制过程产生或起始于板坯/方坯来料。通常,裂纹等各种各样的缺陷大多源于初始铸坯,而非产生于后面的工序。不管是方坯还是板坯,各种缺陷的产生机理是类似的。描述板坯/方坯上存在的各种缺陷,并举例不同工艺条件下这些缺陷的表现形式。此外,还提出判定各种缺陷的一些指导准则。 | Douglas G Stalheim 王厚昕(译) 职建军(校) | 2010 | 世界钢铁2010，，4： | 5 |
| 20 | Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease显示文摘BACKGROUND Studies have demonstrated a potential role for fecal biomarkers such as fecal calprotectin(FC)and fecal lactoferrin(FL)in monitoring inflammatory bowel diseases(IBD)-Crohn's disease(CD)and ulcerative colitis(UC).However,their correlation to endoscopic scores,disease severity and affected intestinal surface has not been extensively investigated.AIM To correlate FL,and for comparison white blood cell(WBC)and C-reactive protein(CRP),with endoscopic scores,disease extent and location in CD and UC.METHODS Retrospective analysis in 188 patients who had FL,CRP and WBC determined within 30 d of endoscopy.Disease location,disease extent(number of intestinal segments involved),disease severity(determined by endoscopic scores),timing of FL testing in relation to colonoscopy,as well as the use of effective fast acting medications(steroids and biologics)between colonoscopy and FL measurement,were recorded.RESULTS In 131 CD and 57 UC patients,both CRP and FL-but not WBC-distinguished disease severity(inactive,mild,moderate,severe).In patients receiving fastacting(steroids or biologics)treatment in between FL and colonoscopy,FL showed a higher correlation to endoscopic scores when tested before vs after the procedure(r=0.596,P<0.001,vs r=0.285,P=0.15 for the Simple Endoscopic Score for CD;and r=0.402,P=0.01 vs r=0.054 P=0.84 for Disease Activity Index).Finally,FL was significantly correlated with the diseased mucosal surface(colon-ileocolon>small bowel)and the number of inflamed colon segments.CONCLUSION FL and CRP separated disease severity categories with FL showing lower discriminating P-values.FL showed a close correlation with the involved mucosal surface and with disease extent and was more closely correlated to endoscopy when determined before the procedure–this indicating that inflammatory activity changes associated with therapy might be rapidly reflected by FL levels.FL can accurately and timely characterize intestinal inflammation in IBD. | Marrieth G Rubio Kofi Amo-Mensah James M Gray Vu Q Nguyen Sam Nakat Douglas Grider Kim Love James H Boone Dario Sorrentino | 2019 | World Journal of Gastrointestinal Pathophysiology2019，10，5： | 4 |
您所在的机构暂未开通此部分的功能，请联系管理员